Print Friendly

All E-Alerts

E-Alerts

FDA ISSUES WARNING ABOUT SERIOUS RISK OF HEAT-RELATED COMPLICATIONS WITH THE ANTINAUSEA PATCH SCOPOLAMINE TRANSDERMAL SYSTEM (TRANSDERM SCŌP) (July 14, 2025)
FDA Issues Warning About Rare but Serious Liver Injury With the Use of Fezolinetant (VEOZAH) for Hot Flashes Due to Menopause (September 16, 2024)
FDA Warns of Dosing Errors of Compounded Injectable Semaglutide Products Marketed for Type 2 Diabetes or Weight Loss (August 15, 2024)
FDA Warns Against Using Smartwatches or Smart Rings for Blood Glucose Monitoring (February 28, 2024)
FDA Requires Boxed Warning for Denosumab (PROLIA) because of an Increased Risk of Severe Hypocalcemia for Some Patients (January 23, 2024)
FDA Issues Warning About Rare but Serious Drug Reaction with the Antiseizure Drugs Levetiracetam and Clobazam (December 1, 2023)
FDA Issues Warning About EzriCare Artificial Tears and Delsam Pharma’s Artificial Tears (February 6, 2023)
FDA Issues Warning Letters to Companies Selling Unapproved Over-The-Counter Skin-Lightening Drug Products (April 25, 2022)
FDA Warns That Buprenorphine Medications Dissolved in Mouth Increase Risk of Dental Problems (January 28, 2022)
FDA Limits Approved Uses of Tofacitinib (XELJANZ, XELJANZ XR) Because of Risks of Serious Adverse Effects (September 22, 2021)

1 of 11